Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108633 | 0.84 | CYP1A2 (0.69) | NPC1RAB9AKDM4EHPGDHTT | |
| SCHEMBL8419625 | 0.81 | VNN1 (0.60) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL30487250 | 0.81 | CXCR4 (0.68) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL229311 | 0.81 | CXCR4 (0.68) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL23938004 | 0.81 | NPC1 (0.62) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL6754285 | 0.81 | MAOA (0.64) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL13757445 | 0.80 | NPC1 (0.74) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL12832443 | 0.80 | CYP2C19 (0.56) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL11563461 | 0.78 | NOS2 (0.58) | NPC1RAB9AKDM4ETP53HPGD | |
| SCHEMBL2397577 | 0.78 | MAOA (0.73) | NPC1RAB9AKDM4ETP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | RETROVIROX, INC. | 2022-12-29 | — | — | US | disclosed |
| EP-1658291-B1 | SUBSTITUTED 8-HETEROARYL XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-8153628-B2 | Pyrazolyl substituted xanthines | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153628-B2 | Pyrazolyl substituted xanthines | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-04-10 | — | — | US | disclosed |
| EP-2295434-A2 | Substituted 8-heteroaryl xanthines | Adenosine Therapeutics, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-7601723-B2 | Pyridyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601723-B2 | Pyridyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | NPC1 1223/4885RAB9A 2666/4885KDM4E 3621/4885 |
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | CD74, HLA-DRB1, MICA | NPC1 1126/4885RAB9A 1829/4885KDM4E 358/4885 |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | NPC1 1411/4885RAB9A 2151/4885KDM4E 3207/4885 |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | NPC1 1005/4885RAB9A 1780/4885KDM4E 1206/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | NPC1 1411/4885RAB9A 2151/4885KDM4E 3207/4885 |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADORA2B, GPR119, ADORA2A | NPC1 1996/4885RAB9A 2745/4885KDM4E 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.